Cell Technologies Shared Resource

Cell Technologies 共享资源

• 批准号: 10332922
• 负责人: RICHARD D SCHULICK
• 金额: --
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-04 至 2027-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10332922
• 关键词: Accounting; Address; Animals; Antibodies; Antigens; Apoptosis; Basic Science; Biochemical; Biological; Biology; Budgets; CRISPR/Cas technology; Cancer Center; Cancer Center Support Grant; Cancer cell line; Cell Culture Techniques; Cell Cycle; Cell Line; Cell Proliferation; Cell Separation; Cells; Cellular biology; Chemotaxis; Colorado; Consult; Consultations; Cultured Cells; Custom; Data Analyses; Development; Drug Screening; Education; Educational Activities; Ensure; Epigenetic Process; Equipment; Exercise; Fee-for-Service Plans; Fees; Funding; Future; Gene Expression; Genes; Genetic Variation; Grant; Hour; Human; Hybridomas; Image; Immunology; Immunology procedure; In Vitro; Insecta; Leadership; Liquid substance; Malignant Neoplasms; Metabolism; Modeling; Monoclonal Antibodies; Mutation; Mycoplasma; NCI Center for Cancer Research; Nitrogen; Organoids; Outcome; Peer Review; Price; Process; Production; Proteins; Publications; Recombinant Proteins; Research; Research Personnel; Research Project Grants; Resource Sharing; Role; Sampling; Services; Site; Study models; Support System; System; Technical Expertise; Techniques; Technology; Time; Tissue Model; Training; Translational Research; Universities; Update; Work; angiogenesis; anticancer research; arm; base; biomarker development; cancer cell; cancer stem cell; cell motility; cellular imaging; cost; cost effective; design; drug development; drug discovery; established cell line; experience; experimental study; extracellular; graduate student; hybridoma production; imaging system; in vivo; instrumentation; interest; lectures; live cell imaging; matrigel; medical schools; member; monoclonal antibody production; nanobodies; novel strategies; pre-clinical; pre-clinical research; programs; real-time images; repository; response; stem cells; structural biology; therapeutic target; tissue culture; translational cancer research; tumor; tumorigenesis

ABSTRACT Overview: The Cell Technologies Shared Resource (CTSR) supports basic and translational research projects for University of Colorado Cancer Center (UCCC) members. CTSR produces hybridomas/monoclonal antibodies to enhance basic research and preclinal studies and makes recombinant proteins for mechanistic and structural studies on proteins. To address the growing importance of organoid-based studies as culture models that better mimic in vivo biology, the CTSR offers training and fee-for-service organoid services. We provide multiple platforms and analytic modules for real time live-cell imaging of cultured cells and organoids to enhance analysis of cancer cell biology. Services and Expertise: CTSR offers over 500 authenticated cell lines enhancing Rigor in Research on our campus, and has over 25 years of experience in generating hybridomas and in producing purified monoclonal antibodies and recombinant proteins to support basic, translational and preclinical research. In this funding period, the SR added state-of-the-art services, training, and consulting focused on use of organoid technologies. Equipment. The CTSR has all required equipment to support isolation of hybridomas, production and purification of monoclonal antibodies, and of recombinant proteins from mammalian or insect cells, and general cell culture. A large capacity liquid nitrogen system stores established cell lines, hybridomas, and other biological samples. The Sartorius IncuCyte imaging system was updated in 2020 and offers real time imaging of living cells to quantitate cell proliferation, apoptosis, cell migration, chemotaxis, cell cycle changes, spheroid cultures, and organoid cultures in an automated, high throughput manner. A Mantis liquid handling system and Olympus IX83 with spinning disk imaging system support organoid culture projects. Management: CTSR is a blended SR managed by UCCC and the School of Medicine. Currently CCSG funding represented 19% of the annual operating budget. The remaining support is from user fees (40%), institutional support (32%), and other center grants (9%). Use of Services: Since July 2016, 244 investigators have used the services. Forty-nine percent of users (119) were UCCC members, representing all four UCCC Programs and resulting in 57 peer- reviewed cancer-relevant publications. Consultation and Education: CTSR provides seminars to inform investigators of the research potential in live cell imaging, and advances in organoid culture; and offers a three- week course on organoids and stem cells for graduate students. The CTSR also participates in a Rigor in Research course offered to graduate students. On-site office hours with a Technical Service Representatives for the IncuCyte systems are offered; and the Directors and Staff routinely consult with investigators on projects to ensure successful outcomes. Future Plans: Organoid-based technologies are advancing rapidly offering new opportunities for basic and translational research. The CTSR will focus on developing techniques and capacities to offer UCCC members cost-effective options to advance their research. In addition, the CTSR will continue to enhance its live cell imaging capacities by adding IncuCyte modules that are of interest to UCCC members.

抽象的 概述：单元技术共享资源（CTSR）支持基本和转化研究项目 科罗拉多大学癌症中心（UCCC）成员。 CTSR产生杂交/单克隆抗体 增强基础研究和初级研究，并制造重组蛋白的机械和结构 蛋白质研究。解决基于器官的研究作为培养模型的日益重要性 CTSR模仿体内生物学，提供培训和费用为服务的器官服务。我们提供多个 实时的平台和分析模块，用于对培养细胞和器官的实时实时现场成像，以增强分析 癌细胞生物学。服务和专业知识：CTSR提供500多个经过身份验证的细胞系，增强严格状态 在我们校园的研究中，在产生杂交瘤和生产方面拥有超过25年的经验 纯化的单克隆抗体和重组蛋白支持基本，转化和临床前研究。 在此资助期间，SR添加了最先进的服务，培训和咨询，专注于使用器官的使用 技术。设备。 CTSR拥有所有必需的设备，以支持杂交局体的隔离，生产 以及单克隆抗体以及哺乳动物或昆虫细胞的重组蛋白的纯化，以及 一般细胞培养。大容量液氮系统存储已建立的细胞系，杂交瘤和其他 生物样品。 Sartorius Incucyte成像系统于2020年更新，并提供了实时成像 活细胞定量细胞增殖，凋亡，细胞迁移，趋化性，细胞周期变化，球形 以自动化的高通量方式进行培养和器官培养。螳螂液体处理系统和 带有旋转磁盘成像系统的Olympus IX83支持器官培养项目。管理：CTSR是一个 由UCCC和医学院管理的SR混合。目前CCSG资金占19％ 年度运营预算。其余的支持来自用户费用（40％），机构支持（32％）和其他 中心补助（9％）。服务的使用：自2016年7月以来，有244名调查人员使用了这些服务。四十九 UCCC成员的用户百分比（119），代表所有四个UCCC计划，并导致57个同行 - 审查了与癌症相关的出版物。咨询和教育：CTSR提供研讨会以告知 研究人员研究了活细胞成像的潜力，以及器官培养的进展；并提供三 研究生的类器官和干细胞课程。 CTSR还严格参加 研究课程向研究生提供。与技术服务代表的现场办公时间 提供了incucyte系统；董事和员工经常向调查人员咨询项目 确保成功的结果。未来计划：基于器官的技术正在迅速提供新的新技术 基础研究和转化研究的机会。 CTSR将专注于开发技术和能力 为UCCC成员提供具有成本效益的选择来推进其研究。此外，CTSR将继续 通过添加UCCC成员感兴趣的incucyte模块来增强其活细胞成像能力。